{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"24","value":"0"}]}],"title":"median VAS score - day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"76","value":"0"}]}],"title":"median VAS score - day 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"60","value":"4.5"}]}],"title":"median VAS score - day 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"95","value":"18.5"}]}],"title":"median VAS score - day 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"92","value":"23.5"}]}],"title":"median VAS score - day 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"80","value":"12.5"}]}],"title":"median VAS score - day 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"90","value":"7"}]}],"title":"median VAS score - day 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"84","value":"3"}]}],"title":"median VAS score - day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"the patient's self-reported assessment of nausea Days 1-8 using a 0-100mm visual analog scale (VAS) median.\n\nThe Visual Analouge (VAS) 100mm Scale Score for Chemotherapy Induced Nausea and Vomiting (CINV). Participants were asked to mark a linear scale 100mm in length representing their level of nausea with 0mm indicating no nausea and 100mm indicating severe nausea. Median VAS scores (in mm) are reported, per day.","dispersionType":"Full Range","groups":[{"description":"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.\n\n\\- Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).\n\nAcute emesis prophylaxis:\n\n* Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.\n* Dexamethasone 20mg PO (orally) daily, D1 and 2\n* Fosaprepitant 150mg IV on day 3\n\nDelayed emesis prophylaxis:\n\n* Fosaprepitant 150mg IV on D5\n* Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8\n\nPRN antiemetics allowed at the discretion of the treating investigator\n\n* No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods\n\nFosaprepitant: Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophyl","id":"OG000","title":"Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"54 patients completed the VAS on all 8 days and were eligible for analysis.","reportingStatus":"POSTED","timeFrame":"Days 1-8 of chemotherapy regimen","title":"Self-Reported Assessment of Nausea","type":"SECONDARY","unitOfMeasure":"millimeters"}